Ondansetron Pharmacology

Quick Answer

Ondansetron is a selective 5-HT₃ (serotonin type 3) receptor antagonist used primarily for the prevention and treatment of postoperative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). It acts by blocking 5-HT₃ receptors both peripherally on vagal afferent nerves in the gastrointestinal tract and centrally in the chemoreceptor trigger zone (CTZ) and nucleus tractus solitarius. The standard PONV prophylaxis dose is 4 mg IV administered at the end of surgery, with a number needed to treat (NNT) of approximately 6 for preventing vomiting. Key pharmacokinetic features include oral bioavailability of 60%, extensive hepatic metabolism primarily via CYP3A4, CYP2D6, and CYP1A2, a volume of distribution of 1.8-2.4 L/kg, and an elimination half-life of 3-6 hours. The most clinically significant adverse effect is dose-dependent QT interval prolongation, prompting FDA warnings and dose limitations (maximum 16 mg IV single dose). Ondansetron is most effective as part of multimodal PONV prophylaxis, combined with dexamethasone for high-risk patients based on Apfel score assessment. [1-8]

Pharmacology Overview

Drug Classification and History

Ondansetron (Zofran®) belongs to the 5-HT₃ receptor antagonist class of antiemetics, representing a significant advancement over older antiemetics such as phenothiazines, butyrophenones, and metoclopramide. Developed by GlaxoSmithKline, ondansetron was the first selective 5-HT₃ antagonist introduced into clinical practice, receiving FDA approval in 1991 initially for CINV and subsequently for PONV. The discovery of 5-HT₃ receptor involvement in the emetic reflex revolutionised antiemetic therapy, providing effective treatment with a superior side effect profile compared to dopamine antagonists, which cause sedation and extrapyramidal symptoms. [1,2]

Chemical Structure and Physicochemical Properties

Ondansetron hydrochloride has the molecular formula C₁₈H₁₉N₃O·HCl·2H₂O with a molecular weight of 365.9 Da (as the dihydrate hydrochloride salt). Structurally, it is a carbazole derivative: 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride dihydrate. The molecule features a planar tricyclic carbazole ring system with a methylimidazole side chain, which is essential for 5-HT₃ receptor binding. Ondansetron is a weak base with a pKa of 7.4, rendering it approximately 50% ionised at physiological pH. It is moderately lipophilic (log P of 2.4), which allows adequate CNS penetration to access central 5-HT₃ receptors. The drug is freely soluble in water (forming a clear, colourless solution), stable at room temperature, and compatible with common intravenous fluids including 0.9% saline and 5% dextrose. [3,4]

Mechanism of Action: 5-HT₃ Receptor Antagonism

Ondansetron exerts its antiemetic effect through selective competitive antagonism of 5-HT₃ receptors, which are ligand-gated cation channels composed of five subunits arranged around a central ion pore. The 5-HT₃ receptor is unique among serotonin receptors as the only ionotropic (rather than metabotropic G-protein coupled) receptor type. When serotonin binds to the 5-HT₃ receptor, the channel opens, allowing rapid influx of sodium and calcium ions, leading to neuronal depolarisation and action potential generation. Ondansetron competitively binds to the receptor with high affinity (Ki approximately 2-10 nM), preventing serotonin binding and subsequent ion channel activation. [5-8]

Peripheral Mechanism: Emetogenic stimuli—including surgical manipulation, chemotherapy, radiotherapy, and gut distension—trigger release of serotonin from enterochromaffin cells in the gastrointestinal mucosa. This serotonin activates 5-HT₃ receptors located on vagal afferent nerve terminals in the gut wall, transmitting signals via the vagus nerve to the nucleus tractus solitarius (NTS) in the brainstem. Ondansetron blocks these peripheral receptors, interrupting afferent transmission of the emetic signal. This peripheral action is particularly important for chemotherapy-induced and radiation-induced emesis, where massive serotonin release from damaged enterochromaffin cells is the primary trigger. [9-11]

Central Mechanism: 5-HT₃ receptors are also densely expressed in the area postrema (chemoreceptor trigger zone, CTZ), which lies outside the blood-brain barrier, and in the nucleus tractus solitarius. The CTZ detects emetogenic substances in the blood and cerebrospinal fluid, while the NTS integrates emetic signals from multiple sources including the vestibular system, higher cortical centres, and vagal afferents. Ondansetron's moderate lipophilicity allows penetration into the CNS, where it antagonises central 5-HT₃ receptors, providing a second line of antiemetic action. The relative contribution of peripheral versus central mechanisms varies with the emetic stimulus; for PONV, both mechanisms appear important. [12-14]

Receptor Selectivity

A critical advantage of ondansetron over older antiemetics is its high selectivity for 5-HT₃ receptors with minimal affinity for other receptor types. Ondansetron has negligible binding to:

This selectivity accounts for ondansetron's favourable side effect profile compared to dopamine antagonists (droperidol, metoclopramide) and phenothiazines (prochlorperazine), which cause sedation, akathisia, and extrapyramidal reactions. [15,16]

Pharmacokinetic Principles

Absorption

Ondansetron is available in multiple formulations: intravenous (most common in anaesthesia), oral tablets, oral disintegrating tablets (ODT), and oral solution. Following oral administration, ondansetron is well absorbed from the gastrointestinal tract, but undergoes significant first-pass hepatic metabolism, resulting in an oral bioavailability of approximately 60% (range 50-70%). Peak plasma concentrations (Cmax) are achieved within 1-2 hours after oral dosing. The orally disintegrating tablet formulation provides equivalent bioavailability to standard tablets but offers convenience for patients unable to swallow. Food does not significantly affect the rate or extent of absorption, though Tmax may be slightly delayed. Rectal suppository formulations are available in some countries with bioavailability of 50-60%. [17-19]

Comparison of Formulations:

Distribution

Ondansetron distributes moderately into tissues with a volume of distribution (Vd) of 1.8-2.4 L/kg in adults, indicating distribution beyond plasma volume into peripheral tissues. Protein binding is moderate at 70-76%, primarily to albumin and α₁-acid glycoprotein. The drug crosses the blood-brain barrier sufficiently to achieve therapeutic concentrations at central 5-HT₃ receptors, supported by its moderate lipophilicity. Ondansetron crosses the placenta with fetal-to-maternal plasma ratios of approximately 0.4-0.6; it is classified as FDA Pregnancy Category B (Australian TGA Category B1). Limited data suggest transfer into breast milk, though the clinical significance is uncertain. [20-22]

Metabolism

Ondansetron undergoes extensive hepatic metabolism via multiple cytochrome P450 pathways, primarily CYP3A4 (major pathway), CYP2D6, and CYP1A2. Metabolism involves hydroxylation followed by glucuronide and sulfate conjugation. The metabolites have minimal 5-HT₃ antagonist activity and do not contribute significantly to the antiemetic effect. CYP2D6 polymorphism is clinically relevant: ultra-rapid CYP2D6 metabolisers may have increased clearance and potentially reduced antiemetic efficacy, though the clinical impact is modest for single-dose prophylaxis. The presence of multiple metabolic pathways provides redundancy; inhibition of a single pathway does not dramatically alter ondansetron clearance. [23-26]

Drug Interactions Affecting Metabolism:

Elimination

Ondansetron is eliminated primarily via hepatic metabolism with less than 5% excreted unchanged in urine. The terminal elimination half-life is 3-6 hours in healthy adults, though there is considerable inter-individual variability. Total body clearance is approximately 25-30 L/hr (0.35-0.5 L/hr/kg). The duration of antiemetic effect (typically 6-12 hours for PONV prophylaxis) extends beyond what would be predicted from the elimination half-life, suggesting receptor binding kinetics or other factors contribute to duration. [27,28]

Special Populations:

Hepatic Impairment

In patients with moderate to severe hepatic impairment (Child-Pugh B or C), ondansetron clearance is reduced by approximately 50%, and the elimination half-life is prolonged to 10-20 hours. The FDA and TGA recommend a maximum single dose of 8 mg intravenously and a maximum daily dose of 8 mg orally in patients with severe hepatic impairment. This dose reduction is critical given the QT prolongation risk, which may be enhanced with elevated plasma concentrations. [29,30]

Clinical Pharmacology

Indications in Anaesthesia

Postoperative Nausea and Vomiting (PONV): Ondansetron is approved for both prophylaxis and treatment of PONV. For prophylaxis, the recommended adult dose is 4 mg IV administered at the end of surgery, typically 20-30 minutes before emergence. This timing takes advantage of the rapid onset (approximately 30 minutes to peak effect) while ensuring therapeutic concentrations during the high-risk early postoperative period. For treatment of established PONV, 4 mg IV can be administered; however, if ondansetron was used for prophylaxis, rescue antiemetics from a different class are preferred. [31-34]

Chemotherapy-Induced Nausea and Vomiting (CINV): Ondansetron is highly effective for prevention of acute CINV (occurring within 24 hours of chemotherapy). Standard dosing is 8 mg IV before chemotherapy or 8 mg orally twice daily. For highly emetogenic chemotherapy (e.g., cisplatin), ondansetron is combined with a corticosteroid (dexamethasone) and an NK₁ receptor antagonist (aprepitant) as part of a three-drug regimen. Ondansetron is less effective for delayed CINV (>24 hours), where corticosteroids and NK₁ antagonists are preferred. [35,36]

Radiation-Induced Nausea and Vomiting: For total body irradiation or radiotherapy to the abdomen, ondansetron 8 mg orally 1-2 hours before each fraction is recommended. [37]

Dosing for PONV

PONV Risk Assessment: Apfel Simplified Score

The Apfel simplified risk score is the most widely used tool for assessing PONV risk and guiding prophylaxis decisions. Each risk factor adds one point:

Risk Stratification:

Additional risk factors not in the simplified score include type of surgery (laparoscopic, gynaecological, strabismus), duration of anaesthesia >60 minutes, and use of volatile anaesthetics over propofol TIVA. [38-42]

Multimodal PONV Prophylaxis

Current consensus guidelines (Fourth Consensus Guidelines for Management of PONV, 2020) recommend multimodal prophylaxis for patients at moderate-to-high risk (Apfel score ≥2). The rationale is that antiemetics with different mechanisms of action provide additive benefit:

Commonly Used Combinations:

Timing of Administration:

• Dexamethasone: At induction (allows anti-inflammatory effects to develop)
• Ondansetron: End of surgery (shorter half-life, covers emergence period)
• Droperidol: End of surgery

Each additional antiemetic reduces relative PONV risk by approximately 25%. The number needed to treat (NNT) for ondansetron monotherapy is approximately 6 for preventing vomiting; when combined with dexamethasone in high-risk patients, the NNT improves to approximately 3-4. [43-46]

Comparison with Other Antiemetics

Ondansetron has equivalent efficacy to droperidol and is superior to metoclopramide 10 mg for PONV prophylaxis. The IMPACT trial (2004) demonstrated that ondansetron 4 mg, droperidol 1.25 mg, and dexamethasone 4 mg each provide approximately 26% relative risk reduction when used alone. [47-50]

Cardiovascular Effects: QT Prolongation

Mechanism of QT Prolongation

Ondansetron prolongs the cardiac QT interval through blockade of the hERG (human Ether-à-go-go Related Gene) potassium channel (IKr current), which is critical for phase 3 repolarisation of the cardiac action potential. This is a class effect of 5-HT₃ antagonists, though the magnitude varies between agents. QT prolongation is dose-dependent, with mean QTc increases of approximately 5-8 msec at 4 mg IV and 15-20 msec at higher doses. The FDA issued a safety communication in 2012 removing the 32 mg IV dose from labelling due to cases of Torsades de Pointes (TdP) associated with high-dose ondansetron. [51-54]

Risk Factors for QT-Related Arrhythmias

QT-Prolonging Drug Interactions:

Concurrent use of ondansetron with other QT-prolonging medications increases arrhythmia risk:

• Antiarrhythmics: Amiodarone, sotalol, procainamide
• Antibiotics: Fluoroquinolones, macrolides
• Antipsychotics: Haloperidol, droperidol
• Antidepressants: TCAs, some SSRIs
• Other antiemetics: Droperidol, domperidone

Clinical Recommendations

1. Standard dose (4 mg IV): QT prolongation is minimal and clinically insignificant in most patients
2. Maximum single IV dose: 16 mg (reduced from 32 mg in 2012)
3. Hepatic impairment: Maximum 8 mg/day
4. High-risk patients: Consider granisetron (less QT effect) or dexamethasone/droperidol low-dose as alternatives
5. ECG monitoring: Not routinely required for 4 mg dose; consider for high-risk patients or repeated dosing

Importantly, the incidence of clinically significant arrhythmias (TdP) with 4 mg ondansetron for PONV is extremely rare, and the benefits generally outweigh risks in most surgical patients. The FDA warning primarily addresses high-dose CINV protocols. [55-57]

Adverse Effects and Complications

Common Adverse Effects

Serious Adverse Effects

QT Prolongation and Torsades de Pointes: As discussed above, dose-dependent QT prolongation can predispose to TdP, particularly in patients with risk factors. Fatal arrhythmias have been reported, prompting FDA safety communications. [51-57]

Serotonin Syndrome: Although ondansetron does not bind 5-HT₁ or 5-HT₂ receptors, rare cases of serotonin syndrome have been reported when combined with other serotonergic drugs (SSRIs, SNRIs, tramadol, fentanyl). The mechanism is unclear but may involve altered serotonin metabolism. Symptoms include agitation, hyperthermia, tachycardia, hyperreflexia, and tremor. [58,59]

Hypersensitivity Reactions: Rare anaphylaxis and anaphylactoid reactions have been reported. Cross-sensitivity may exist with other 5-HT₃ antagonists (granisetron, tropisetron). [60]

Contraindications

Drug Interactions

The tramadol interaction is clinically relevant in the postoperative setting: ondansetron may reduce the analgesic efficacy of tramadol by blocking 5-HT₃ receptors involved in descending pain modulation. Alternative antiemetics (dexamethasone, droperidol) may be preferred when tramadol is the primary analgesic. [61-63]

Australian/NZ Specific Considerations

TGA-Approved Formulations

Ondansetron is TGA-approved in Australia in multiple formulations:

The injection solution is stable at room temperature (up to 25°C), does not require refrigeration, and is compatible with 0.9% saline, 5% dextrose, and Hartmann's solution. It should not be mixed in the same syringe as other medications due to compatibility concerns. [64,65]

PBS Listing

Ondansetron is listed on the Pharmaceutical Benefits Scheme (PBS) under several categories:

General Schedule (Authority Required):

• Prevention or treatment of nausea and vomiting associated with cancer chemotherapy
• Prevention or treatment of nausea and vomiting associated with radiotherapy

Section 100 (Highly Specialised Drugs):

• Not applicable for ondansetron

Hospital Formulary:

• Ondansetron for PONV is generally available on hospital formularies without PBS authority, funded through hospital drug budgets
• Cost per 4 mg ampoule: approximately AUD $2-5 (generic) to $10-15 (branded)

For outpatient PONV prophylaxis or treatment, ondansetron is available over-the-counter (OTC) as a Pharmacist Only Medicine (Schedule 3) in limited quantities for nausea associated with migraine or radiotherapy in some formulations. [66,67]

ANZCA Guidelines

The Australian and New Zealand College of Anaesthetists endorses evidence-based PONV prophylaxis as outlined in the Fourth Consensus Guidelines. ANZCA PS04 (Guidelines for the Conduct of Anaesthesia) recommends assessment of PONV risk preoperatively and appropriate prophylaxis for at-risk patients. ANZCA supports the multimodal approach combining ondansetron with dexamethasone for patients with Apfel score ≥2, and emphasises opioid-sparing analgesia and avoidance of volatile anaesthetics (where appropriate) as non-pharmacological risk reduction strategies. [68]

Indigenous Health Considerations

Limited pharmacokinetic data exist specifically for Aboriginal and Torres Strait Islander populations regarding ondansetron. However, several clinical and cultural factors warrant consideration in perioperative care. Higher rates of chronic liver disease (related to hepatitis B/C and alcohol-related liver disease) in some Indigenous communities may affect ondansetron metabolism; in patients with suspected or known hepatic impairment, the maximum daily dose should be limited to 8 mg, and alternative antiemetics (dexamethasone) may be preferred.

Remote and rural communities with high Indigenous populations may have limited access to specialist anaesthesia services and comprehensive PONV prophylaxis protocols. Where possible, multimodal prophylaxis should still be implemented, recognising that ondansetron is generally available in remote health facilities. Patient education about PONV and the purpose of antiemetic medications should be delivered through culturally appropriate communication, involving Aboriginal Health Workers or interpreters where beneficial. Family involvement in perioperative care decisions (consistent with concepts of kinship and collective decision-making) should be supported.

Māori health considerations in New Zealand similarly emphasise culturally safe care with whānau (family) involvement. Higher rates of obesity and metabolic syndrome in Māori populations may increase PONV risk, supporting proactive prophylaxis in these patients.

ANZCA Primary Exam Focus

Common MCQ Patterns

ANZCA Primary MCQs frequently test the following ondansetron and antiemetic concepts:

1. Mechanism of action: Selective 5-HT₃ receptor antagonism (NOT D₂, NOT muscarinic)
2. Receptor type: 5-HT₃ is a ligand-gated ion channel (ionotropic, NOT G-protein coupled)
3. Site of action: Peripheral (vagal afferents) AND central (CTZ, NTS)
4. Pharmacokinetics: Oral bioavailability 60%, hepatic metabolism via CYP3A4/2D6/1A2, t½ 3-6 hours
5. Dosing: 4 mg IV for PONV prophylaxis, administered at end of surgery
6. Adverse effects: QT prolongation (dose-dependent), headache, constipation
7. Apfel score: Female, non-smoker, history of PONV/motion sickness, postoperative opioids
8. Multimodal prophylaxis: Ondansetron + dexamethasone for Apfel ≥2
9. Drug comparisons: Ondansetron vs droperidol vs metoclopramide efficacy
10. Drug interactions: Tramadol (↓ analgesia), CYP3A4 inducers (↓ effect)

Primary Viva Question Themes

Viva scenarios typically explore:

• Patient with high PONV risk: selection and combination of antiemetics
• Management of PONV despite prophylaxis: rescue antiemetic selection
• Patient with Long QT syndrome requiring PONV prophylaxis: alternative agents
• Ondansetron mechanism of action in molecular detail
• Comparison of antiemetic classes and their clinical applications
• Multimodal PONV prevention including non-pharmacological strategies

Calculation Questions

Candidates should be comfortable with:

• Paediatric ondansetron dosing: 0.1 mg/kg IV (maximum 4 mg)
• Calculating PONV risk using Apfel score and selecting appropriate prophylaxis
• Understanding NNT concept: NNT of 6 means treating 6 patients prevents 1 episode of vomiting

Assessment Content

SAQ Practice Question (20 marks)

Question:

A 35-year-old woman (65 kg) is scheduled for laparoscopic cholecystectomy under general anaesthesia. She is a non-smoker with a history of motion sickness. She has no cardiac history, takes no regular medications, and has a normal ECG preoperatively. Postoperative opioid analgesia (morphine PCA) is planned.

(a) Calculate this patient's Apfel score and estimated baseline risk of postoperative nausea and vomiting. Outline your prophylaxis strategy based on this risk assessment. (5 marks)

(b) Describe the mechanism of action of ondansetron at the molecular and physiological level, including the sites of action relevant to PONV prevention. (6 marks)

(c) Discuss the pharmacokinetic properties of ondansetron, including absorption, distribution, metabolism, and elimination. Explain how hepatic impairment would alter your dosing. (5 marks)

(d) The patient asks about side effects of ondansetron. Explain the mechanism and clinical significance of QT prolongation, and identify patients in whom alternative antiemetics should be considered. (4 marks)

---

Model Answer:

(a) Apfel Score and Prophylaxis Strategy (5 marks)

Apfel Score Calculation (3 marks):

Apfel Score: 4/4 → Estimated baseline PONV risk: 79% (approximately 80%)

Prophylaxis Strategy (2 marks):

• High-risk patient requires multimodal prophylaxis
• Recommended regimen:
  • Ondansetron 4 mg IV at end of surgery
  • Dexamethasone 4-8 mg IV at induction
  • Consider third agent (droperidol 0.625-1.25 mg) OR
  • Total IV anaesthesia (TIVA) with propofol
  • Opioid-sparing analgesia (paracetamol, NSAIDs, local anaesthetic infiltration)

(b) Mechanism of Action (6 marks)

Molecular mechanism (3 marks):

• Ondansetron is a selective competitive antagonist at 5-HT₃ receptors
• 5-HT₃ receptor is a ligand-gated ion channel (ionotropic) composed of 5 subunits
• When serotonin binds, the channel opens → Na⁺/Ca²⁺ influx → neuronal depolarisation
• Ondansetron competitively binds with high affinity (Ki ~2-10 nM), preventing serotonin binding and ion channel activation

Sites of action (3 marks):

• Peripheral (vagal afferents): Emetogenic stimuli (surgery, chemotherapy) trigger serotonin release from enterochromaffin cells in GI tract → activates 5-HT₃ receptors on vagal afferent nerves → signals transmitted to brainstem. Ondansetron blocks this peripheral pathway.
• Central (CTZ and NTS): 5-HT₃ receptors in chemoreceptor trigger zone (area postrema, outside blood-brain barrier) and nucleus tractus solitarius (integrates emetic signals). Ondansetron crosses BBB due to moderate lipophilicity and blocks central receptors.

(c) Pharmacokinetics (5 marks)

Hepatic Impairment (2 marks):

• Clearance reduced by ~50% in moderate-severe hepatic impairment
• Half-life prolonged to 10-20 hours
• Dose adjustment: Maximum 8 mg IV single dose, maximum 8 mg/day total
• Rationale: Reduced metabolism → elevated plasma levels → increased QT prolongation risk

(d) QT Prolongation (4 marks)

Mechanism (2 marks):

• Ondansetron blocks hERG potassium channels (IKr current) in cardiac myocytes
• IKr is responsible for phase 3 repolarisation of the cardiac action potential
• Blockade → delayed repolarisation → prolonged QT interval
• Dose-dependent: ~5-8 msec at 4 mg, ~15-20 msec at higher doses

Clinical Significance (1 mark):

• QT prolongation predisposes to Torsades de Pointes (TdP), a polymorphic ventricular tachycardia
• Risk is low with standard 4 mg dose but prompted FDA removal of 32 mg dose

Patients requiring alternative antiemetics (1 mark):

• Congenital Long QT Syndrome (LQTS) — contraindicated
• Baseline QTc >450 ms (males) or >470 ms (females)
• Concurrent QT-prolonging medications
• Uncorrected hypokalaemia or hypomagnesaemia
• Alternatives: Dexamethasone, low-dose droperidol (with monitoring), scopolamine

Total: 20 marks

---

Primary Viva Scenario (15 marks)

Examiner: You are asked to review a 28-year-old woman in the recovery room following laparoscopic appendicectomy. She is vomiting despite having received ondansetron 4 mg and dexamethasone 8 mg prophylaxis. How would you approach this situation?

Candidate:

Initial Assessment (3 marks):

"I would perform a systematic assessment to identify the cause of ongoing PONV and any contributing factors.

First, I would confirm adequacy of prophylaxis—timing and doses of ondansetron and dexamethasone. I would check for reversible causes: hypotension, hypoxia, pain (which can contribute to nausea), gastric distension, and motion from transport.

I would also consider her baseline risk—likely high given she is female and had laparoscopic surgery, though I don't know her full Apfel score."

Examiner: She received ondansetron 4 mg at the end of surgery and dexamethasone 8 mg at induction. She is haemodynamically stable, well-oxygenated, and reports mild pain controlled with IV paracetamol. What rescue treatment would you give?

Candidate:

Rescue Antiemetic Selection (4 marks):

"When prophylaxis fails, the rescue antiemetic should be from a different pharmacological class than those already administered. Since she has received a 5-HT₃ antagonist and a corticosteroid, I would choose a D₂ antagonist.

My first choice would be droperidol 0.625-1.25 mg IV. Droperidol is effective for both nausea and vomiting, with a similar efficacy profile to ondansetron. At low doses, the QT prolongation risk is comparable to ondansetron and is generally acceptable in a young patient without cardiac history.

Alternative options include:

• Prochlorperazine 12.5 mg IV/IM (phenothiazine D₂ antagonist)
• Cyclizine 50 mg IV (H₁ antagonist, also has muscarinic effects)

I would avoid repeating ondansetron, as the same-class rescue has limited additional efficacy when prophylaxis has failed."

Examiner: The nurse asks why you don't just give more ondansetron. Can you explain?

Candidate:

Rationale for Different-Class Rescue (3 marks):

"Re-dosing ondansetron when the initial dose has failed provides limited additional benefit because:

1. Receptor occupancy: At therapeutic doses, ondansetron achieves high 5-HT₃ receptor occupancy. Additional doses provide minimal incremental receptor blockade.

2. Different pathways: PONV involves multiple neurotransmitter pathways—serotonin, dopamine, histamine, muscarinic. If 5-HT₃ blockade is insufficient, targeting a different pathway (D₂ with droperidol) attacks a different component of the emetic circuitry.

3. Dose-dependent toxicity: Higher ondansetron doses increase QT prolongation risk without proportionate efficacy gain.

The consensus guidelines recommend rescue with a different antiemetic class for this reason."

Examiner: If this patient had a history of congenital Long QT Syndrome, how would you have approached her PONV prophylaxis differently?

Candidate:

PONV Prophylaxis in Long QT Syndrome (3 marks):

"In a patient with congenital LQTS, ondansetron is relatively contraindicated due to its hERG channel blockade and QT-prolonging effect. I would avoid ondansetron and droperidol (which also prolongs QT).

Alternative prophylaxis regimen:

• Dexamethasone 4-8 mg IV at induction — no QT effect, effective for nausea
• Scopolamine transdermal patch (apply night before or 2 hours pre-op) — H₁/muscarinic antagonist, no QT effect
• Cyclizine 50 mg IV — H₁ antagonist with minimal QT effect
• Metoclopramide 10 mg IV — weak efficacy but no QT prolongation

Additionally, I would implement non-pharmacological strategies:

• Propofol TIVA (avoid volatile anaesthetics which increase PONV)
• Opioid-sparing analgesia (regional techniques, NSAIDs, paracetamol)
• Adequate hydration
• Minimise gastric insufflation if using airway devices

I would also ensure perioperative monitoring includes continuous ECG with attention to QT interval, avoidance of hypokalaemia and hypomagnesaemia, and avoidance of other QT-prolonging medications."

Examiner: Thank you. Good understanding demonstrated.

Total: 15 marks (3 + 4 + 3 + 3 + 2 for overall structure and completeness)

---

References

1. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998;55(2):173-189. PMID: 9506240

2. Cubeddu LX. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology. 1996;53 Suppl 1:18-25. PMID: 8692546

3. Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet. 1995;29(2):95-109. PMID: 7586904

4. Pritchard JF. Ondansetron metabolism and pharmacokinetics. Semin Oncol. 1992;19(4 Suppl 10):9-15. PMID: 1387253

5. Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets. 2007;11(4):527-540. PMID: 17373882

6. Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor—the relationship between structure and function. Neuropharmacology. 2009;56(1):273-284. PMID: 18761359

7. Costall B, Naylor RJ. 5-HT3 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3(1):27-37. PMID: 14965242

8. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-2494. PMID: 18525044

9. Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci. 2006;129(1-2):3-16. PMID: 16934536

10. Minami M, Endo T, Hirafuji M, et al. Pharmacological aspects of chemotherapy-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther. 2003;99(2):149-165. PMID: 12888110

11. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;111 Suppl 8A:106S-112S. PMID: 11749934

12. Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinol. 1994;15(4):301-320. PMID: 7895890

13. Higgins GA, Kilpatrick GJ, Bunce KT, Jones BJ, Tyers MB. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol. 1989;97(1):247-255. PMID: 2720314

14. Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol. 1990;68(2):325-345. PMID: 2178748

15. Gyermek L. 5-HT3 receptors: pharmacologic and therapeutic aspects. J Clin Pharmacol. 1995;35(9):845-855. PMID: 8786229

16. Gan TJ. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-238. PMID: 15740177

17. Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2000;59(6):1297-1315. PMID: 10882164

18. Christofaki M, Papaioannou A. Ondansetron: a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting. Expert Opin Drug Metab Toxicol. 2014;10(3):437-444. PMID: 24471415

19. Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85-113. PMID: 24356162

20. Spector JI, Lester EP, Chevlen EM, et al. A comparison of oral ondansetron and intravenous metoclopramide in preventing nausea and emesis associated with cancer chemotherapy. N Engl J Med. 1990;322(12):816-821. PMID: 2137903

21. Danielak D, Glowka FK. Impact of CYP2D6 phenotype on ondansetron pharmacokinetics and dynamics. Pharmacogenomics. 2009;10(4):689-695. PMID: 19374524

22. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology. 2005;102(3):543-549. PMID: 15731591

23. Fischer V, Vickers AE, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos. 1994;22(2):269-274. PMID: 8013283

24. Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995;23(11):1225-1230. PMID: 8591723

25. Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218. PMID: 28002639

26. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350(24):2441-2451. PMID: 15190136

27. Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999;91(3):693-700. PMID: 10485781

28. Koivuranta M, Läärä E, Snåre L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52(5):443-449. PMID: 9165963

29. Fiore JF Jr, Gan TJ, Englesbe MJ, et al. Consensus guidelines for postoperative nausea and vomiting: a narrative review. J Am Coll Surg. 2020;231(3):299-310. PMID: 32679262

30. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology. 1997;87(6):1277-1289. PMID: 9416710

31. Sun R, Klein KW, White PF. The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery. Anesth Analg. 1997;84(2):331-336. PMID: 9024022

32. Tang J, Wang B, White PF, Watcha MF, Qi J, Wender RH. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg. 1998;86(2):274-282. PMID: 9459232

33. Henzi I, Walder B, Tramèr MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg. 2000;90(1):186-194. PMID: 10624999

34. Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. Anesth Analg. 2000;91(1):136-139. PMID: 10866900

35. Kazemi-Kjellberg F, Henzi I, Tramèr MR. Treatment of established postoperative nausea and vomiting: a quantitative systematic review. BMC Anesthesiol. 2001;1(1):2. PMID: 11734064

36. Habib AS, El-Moalem HE, Gan TJ. The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials. Can J Anaesth. 2004;51(4):311-319. PMID: 15064258

37. Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006;(3):CD004125. PMID: 16856030

38. Kranke P, Eberhart LH. Possibilities and limitations in the pharmacological management of postoperative nausea and vomiting. Eur J Anaesthesiol. 2011;28(11):758-765. PMID: 21799417

39. Hafermann MJ, Namdar R, Engstrom SM, Thompson AM, Schneider A. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53-58. PMID: 22046106

40. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102(6):1094-1100. PMID: 15915020

41. Kuryshev YA, Brown AM, Wang L, Benedict CR, Bhagwan N. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2010;334(1):21-32. PMID: 20375199

42. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19-25.e6. PMID: 24314899

43. US Food and Drug Administration. FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). 2012. Available at: www.fda.gov

44. Liang Y, Kimball AB, Engstrom SM, et al. Effects of ondansetron on QTc interval and arrhythmia risk: a prospective, observational study of hospitalized patients. Ann Pharmacother. 2014;48(8):981-986. PMID: 24781320

45. Rojas-Fernandez CH, Cameron JC. Is Stemetil (prochlorperazine) associated with QT prolongation and torsades de pointes? A systematic review. Ann Pharmacother. 2012;46(6):932-935. PMID: 22619472

46. Kovac AL. Comparative pharmacology and guide to the use of the serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting. Drugs. 2016;76(18):1719-1735. PMID: 27771882

47. Büttner M, Walder B, von Elm E, Tramèr MR. Is low-dose haloperidol a useful antiemetic?: A meta-analysis of published and unpublished randomized trials. Anesthesiology. 2004;101(6):1454-1463. PMID: 15564955

48. Habib AS, Gan TJ. Combination therapy for postoperative nausea and vomiting—a more effective prophylaxis? Ambul Surg. 2001;9(2):59-71. PMID: 11454480

49. Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007;99(2):202-211. PMID: 17540667

50. Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2020;131(2):411-448. PMID: 32467512

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols.